Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep-Oct;12(5):70-83.

Cardiovascular outcomes and safety with antidiabetic drugs

Khaled K Aldossari  1
Affiliations
Review

Cardiovascular outcomes and safety with antidiabetic drugs

Khaled K Aldossari. Int J Health Sci (Qassim). 2018 Sep-Oct.

Abstract

Type 2 diabetes is a debilitating disease that impacts the life expectancy, quality of life, and health of an individual. Cardiovascular disease (CVD) is a common diabetes-associated complication and a principal cause for death in diabetic patients. This review aims to investigate and summarize the effect of Type 2 diabetes mellitus (T2DM) medications on CVD issues. A comprehensive literature review mainly from level 1 evidence was performed. Thirty-seven articles were extracted from Google Scholar, ScienceDirect, ProQuest, and PubMed Database using a combination of keywords. The findings suggest that different glucose-lowering agents have been tested for their efficacy and safety in T2DM with CVD. Some of the recent trials such as the "United Kingdom Prospective Diabetes Study," "Empagliflozin (EMPA) Cardiovascular (CV) Outcome Event Trial in T2DM Patients-Removing Excess Glucose" (EMPA-REG OUTCOME), "Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results," and "Trial to Evaluate CV and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes" (SUSTAIN6) have shed important light on this vital clinical concern, thus demonstrating a convincing effect of liraglutide, semaglutide, and EMPA on CVD outcomes, while metformin is thought to be the first-line optimal oral agent to manage Type 2 diabetics. Some classes of drugs demonstrate CV protection, some of them may be a result of a class effect, and some differences might be based on the population enrolled individually. Most of the trials failed to show a significant benefit with regard to mortality and morbidity in spite of intensive glycemic control. This study, therefore, enabled us to develop a guide of potential antidiabetic medication that can influence or promote CV health. Health professionals in future should weigh the CV risk against possible advantages while prescribing antidiabetic medications.

Keywords: Antidiabetic drugs; cardiovascular impact; cardiovascular risk; diabetes medications; type 2 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Evidence hierarchy[14]
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bahijri SM, Jambi HA, Al Raddadi RM, Ferns G, Tuomilehto J. The prevalence of diabetes and prediabetes in the adult population of Jeddah, Saudi Arabia–a community-based survey. PLoS One. 2016;11:e0152559. - PMC - PubMed
    1. Robert AA, Al Dawish MA, Braham R, Musallam MA, Al Hayek AA, Al Kahtany NH, et al. Type 2 diabetes mellitus in saudi arabia:Major challenges and possible solutions. Curr Diabetes Rev. 2017;13:59–64. - PubMed
    1. WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Dept. of Noncommunicable Disease Surveillance:WHO. 1999. [[Last accessed on 2017 Jul 30]]. Available from: http://www.apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pd... .
    1. National Institute for Health and Care Excellence. Type 2 diabetes in Adults:Management of type 2 Diabetes in Adults. 2015. [[Last accessed 0n 2017 Jul 30]]. Available from: http://www.tinyurl.com/jucd4r4 .
    1. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. et al. JBS 2:Joint british societies'guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl 5):1–52. - PMC - PubMed

LinkOut - more resources